Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

Cardiomyopathy VI: Nursing Management

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Muscle-targeted extracellular vesicles for full-length dystrophin mRNA therapy in Duchenne muscular dystrophy.

Nature biomedical engineering·2026

Same author

Variation in <i>SNX29</i> and Acute Vasodilator Response in Pulmonary Arterial Hypertension.

Circulation research·2026

Same author

Empagliflozin preserves cardiac function and modulates metabolism in a mouse model of Duchenne muscular dystrophy.

bioRxiv : the preprint server for biology·2026

Same author

BACH2 links β1-adrenergic receptor/β-arrestin1 signaling to MIAT to inhibit cardiac fibroblast activation and cardiomyocyte apoptosis.

Cell death discovery·2026

Same author

IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.

Pharmacological research·2026

Same author

Epicardial and paracardial adipose tissue quantification in short-axis cardiac cine MRI using deep learning.

Magma (New York, N.Y.)·2025

Search research articles

Related Experiment Video

Updated: Feb 10, 2026

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening

Published on: October 4, 2017

Regenerative Therapy for Cardiomyopathies.

Zi Wang¹, Xuan Su¹, Muhammad Ashraf²

¹Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 160, Pujian Road, Shanghai, 200127, China.

Journal of Cardiovascular Translational Research

|May 11, 2018

Summary

Stem cell therapy shows promise for treating heart disease by improving heart function and reducing scar size. Microvesicles like exosomes also offer new therapeutic avenues for cardiovascular diseases.

Keywords:

Angiogenesis Exosomes Ischemic heart diseases Microvesicles Non-ischemic heart diseases Stem cells

More Related Videos

Mechanical Micronization of Lipoaspirates for Regenerative Therapy

Mechanical Micronization of Lipoaspirates for Regenerative Therapy

Published on: March 15, 2019

Author Spotlight: Development and Evaluation of a Standardized Rat Model for Calvarial Suture-Bony Composite Defects

Author Spotlight: Development and Evaluation of a Standardized Rat Model for Calvarial Suture-Bony Composite Defects

Published on: May 10, 2024

Related Experiment Videos

Last Updated: Feb 10, 2026

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening

3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening

Published on: October 4, 2017

Mechanical Micronization of Lipoaspirates for Regenerative Therapy

Mechanical Micronization of Lipoaspirates for Regenerative Therapy

Published on: March 15, 2019

Author Spotlight: Development and Evaluation of a Standardized Rat Model for Calvarial Suture-Bony Composite Defects

Author Spotlight: Development and Evaluation of a Standardized Rat Model for Calvarial Suture-Bony Composite Defects

Published on: May 10, 2024

Area of Science:

Cardiology
Regenerative Medicine
Biotechnology

Background:

Cardiovascular diseases (CVDs) are a leading global cause of death.
Despite advances, effective treatments for myocardial dysfunction are limited.
Stem cell therapy is an emerging treatment for heart conditions.

Purpose of the Study:

To review stem cell types and their applications in ischemic and non-ischemic heart diseases.
To highlight the clinical benefits of stem cells in cardiac repair.
To explore the potential of microvesicles, such as exosomes, in CVD treatment.

Main Methods:

Comprehensive literature review of stem cell therapy in cardiovascular diseases.
Analysis of studies on stem cell efficacy in improving myocardial structure and function.
Evaluation of research on microvesicle-based therapies for heart conditions.

Main Results:

Stem cells demonstrate potential to enhance myocardial structure and function.
Stem cell therapy can promote microvascular angiogenesis and reduce scar size.
Microvesicles, including exosomes, show therapeutic promise for CVDs.

Conclusions:

Stem cell therapy offers a promising approach for treating heart disease.
Further clinical studies on stem cells and microvesicles are warranted for CVDs.
Novel therapeutic strategies are emerging for cardiovascular disease management.